- Prev close
- $460.28
- Day range
- $447.04 – $462.91
AMGN’s 0.7% decline came alongside a weaker tape and similar pressure in peers, while the business still shows 9.1% TTM revenue growth and 31.7% TTM EPS growth; the setup looks mixed rather than deteriorating.
AMGN
AMGEN INC
As of Nov 3, 2026
63/100
Worth keeping an eye onHealth ScoreWhy it moved
AMGN fell -0.7% in the session, which was milder than the S&P 500 at -0.5% and the Nasdaq 100 at -1.4%, and broadly in line with peers ABBV at -1.0% and GILD at -0.2%. That makes the move look primarily sector- and market-driven, not stock-specific. The intraday path was also orderly: it opened at $464.285, traded to $467.04, then finished at $462.42, so the close reflected a modest fade rather than a disorderly sell-off.
Normal volatility?
This looks like ordinary volatility for a large-cap healthcare name, not a fundamentals break. The business still shows revenue growth of +9.1% YoY (TTM), latest quarter revenue growth of +9.5% YoY, and EPS growth of +31.7% YoY (TTM), with gross margin +74.3%, operating margin +30.3%, and net margin +22.9%. Valuation is not cheap at PE 28.8 and forward PE 19.2, and the PEG is 5.89 — PEG is price/earnings divided by growth, so a high reading means strong growth is already priced in and can amplify moves. Beta is -0.65, which helps explain why the stock may not track the market cleanly, but there is no sign here of deteriorating fundamentals or a cut analyst view to justify calling the move more than routine noise.
Earnings preview
The next earnings date is 2026-11-03. The facts do not include a consensus revenue or EPS estimate for this print, so I cannot quote expected growth for the report. The available third-party analyst distribution is 6 strong-positive, 12 positive, 20 neutral, 3 negative, and 1 strong-negative, which points to a mixed but still broadly constructive sell-side backdrop. With revenue up +9.1% YoY (TTM), EPS up +31.7% YoY (TTM), and margins at +74.3% gross, +30.3% operating, and +22.9% net, the market is likely focused on three things: whether recent growth holds, whether margins stay near these levels, and whether the company can defend the premium valuation of PE 28.8 and forward PE 19.2.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track AMGN with WhyIHold
Get a plain-English explanation the next time AMGEN INC makes a big move — so you know whether it's benign or worth your attention.